The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The evolving landscape of drug products containing nanomaterials in the United States
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
DLS and zeta potential – What they are and what they are not?
Bhattacharjee, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.017 · Cited by 4,702
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Risks, Release and Concentrations of Engineered Nanomaterial in the Environment
Giese, B., Klaessig, F., Park, B., Kaegi, R., Steinfeldt, M., Wigger, H., von Gleich, A., & Gottschalk, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19275-4 · Cited by 429
Challenges in nanomedicine clinical translation
Metselaar, J. M., & Lammers, T. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00740-5 · Cited by 396
The role of liposomes in clinical nanomedicine development. What now? Now what?
Crommelin, D. J. A., van Hoogevest, P., & Storm, G. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.023 · Cited by 349
Caputo, F., Clogston, J., Calzolai, L., Rösslein, M., & Prina-Mello, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.030 · Cited by 337
Vu, V. P., Gifford, G. B., Chen, F., Benasutti, H., Wang, G., Groman, E. V., Scheinman, R., Saba, L., Moghimi, S. M., & Simberg, D. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0344-3 · Cited by 309
Nanomaterials for T-cell cancer immunotherapy
Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 306
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Sun, D., Zhou, S., & Gao, W. (2020) · ACS Nano · doi:10.1021/acsnano.9b09713 · Cited by 263
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
Su, S., & M. Kang, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090837 · Cited by 259
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
Agrahari, V., & Agrahari, V. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.047 · Cited by 253
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?
Mühlebach, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.024 · Cited by 203
de Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0329-7 · Cited by 100
Self-citationJoy, R., George, J., & John, F. (2022) · ChemistrySelect · doi:10.1002/slct.202104045 · Cited by 50
Hu, Y., Crist, R. M., & Clogston, J. D. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-02252-9 · Cited by 49
Tyner, K. M., Zheng, N., Choi, S., Xu, X., Zou, P., Jiang, W., Guo, C., & Cruz, C. N. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0084-6 · Cited by 33
Self-citation
Metadata
- Authors
- D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M.
- Venue
- Nature Nanotechnology
- Published
- 2017-04-24
- Volume
- 12
- Issue
- 6
- Pages
- 523-529
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2606017739
- Cited by
- 345
- References
- 48
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.